Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LUFYLLIN vs ELIXOMIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LUFYLLIN (dyphylline) is a xanthine bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway hyperresponsiveness. It also antagonizes adenosine receptors.
ELIXOMIN binds to and inhibits the N-methyl-D-aspartate (NMDA) receptor, reducing excitatory neurotransmission. It also modulates gamma-aminobutyric acid (GABA) activity, enhancing inhibitory signaling.
FDA-approved: Relief and prevention of bronchospasm associated with asthma, chronic bronchitis, and emphysema.,Off-label: Apnea of prematurity, COPD exacerbations.
Treatment of refractory epilepsy,Adjunctive therapy for complex partial seizures,Off-label: neuropathic pain management,Off-label: bipolar disorder maintenance
200-400 mg orally 3-4 times daily, not to exceed 1600 mg/day. Also available as 200 mg/m L injection, administer 200-400 mg IM or slow IV every 6-8 hours.
500 mg orally once daily with a full glass of water, regardless of meals.
6-8 hours in adults with normal hepatic and renal function. In neonates, half-life is prolonged to 20-30 hours. In patients with hepatic cirrhosis, half-life may extend to 20-30 hours. In congestive heart failure, half-life is prolonged to 12-20 hours.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; extends to 24-36 hours in moderate renal impairment (Cr Cl 30-50 m L/min).
Dyphylline is not metabolized by the liver; it is primarily excreted unchanged by the kidneys. Approximately 80% is eliminated unchanged in urine.
Primarily metabolized by CYP3A4 and CYP2C19 isoenzymes; undergoes glucuronidation via UGT1A4. Active metabolite: N-desethyl-ELIXOMIN.
Primarily renal excretion of unchanged drug and metabolites. Approximately 50% is excreted unchanged in urine, with the remainder as metabolites (including 7-hydroxypropyltheophylline and 1,3-dimethyluric acid). Biliary/fecal elimination accounts for <10%.
Renal elimination of unchanged drug accounts for 60-70% of clearance; biliary/fecal excretion accounts for 20-25%; the remainder is metabolized hepatically with inactive metabolites excreted renally.
Approximately 40-50% bound to plasma proteins, primarily albumin.
98% bound to albumin and alpha-1-acid glycoprotein.
0.5-0.7 L/kg. This indicates distribution into total body water with some tissue binding.
0.6-0.8 L/kg; distributes rapidly into total body water, with moderate tissue binding.
Oral immediate-release: 90-100%. Rectal: approximately 80-90%. Sustained-release: 70-90% with delayed absorption.
Oral: 70-80% (due to first-pass metabolism); Intramuscular: 90-95%.
Cr Cl 30-50 m L/min: administer 50-75% of normal dose. Cr Cl <30 m L/min: administer 25-50% of normal dose. Consider monitoring theophylline levels.
GFR > 60 m L/min: no adjustment; GFR 30-60 m L/min: 250 mg once daily; GFR 15-29 m L/min: 125 mg once daily; GFR < 15 m L/min or dialysis: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: administer 50% of normal dose. Child-Pugh C: avoid use or administer 25% of normal dose with close monitoring.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% (250 mg once daily); Class C: not recommended.
Children <1 year: 100-200 mg/day in 3-4 divided doses. Children 1-9 years: 200-300 mg/day in 3-4 divided doses. Children 9-16 years: 200-400 mg/day in 3-4 divided doses. Weight-based alternative: 10-20 mg/kg/day in 3-4 divided doses.
Weight ≥ 40 kg: 500 mg once daily; Weight 20-39 kg: 250 mg once daily; Weight < 20 kg: not established.
Initiate at lower end of dosing range (200 mg 3 times daily). Monitor theophylline levels and adjust dose to maintain trough concentration of 5-15 mcg/m L. Reduce dose if concurrent medications affecting hepatic metabolism.
No specific dose adjustment except based on renal function. Monitor for increased risk of QT prolongation and electrolyte disturbances. Initial dose should be 250 mg once daily if Cr Cl < 60 m L/min.
No FDA black box warning.
WARNING: Risk of suicidal thoughts and behaviors; monitor for worsening depression or emergence of suicidal ideation.
Use with caution in patients with peptic ulcer disease, hyperthyroidism, hypertension, cardiac arrhythmias, or seizure disorders. Monitor serum levels for toxicity. Risk of ventricular arrhythmias or seizures at high doses.
Hepatotoxicity (monitor LFTs); hematologic effects (thrombocytopenia, neutropenia); severe dermatologic reactions (SJS/TEN); pancreatitis; hyperammonemia; somnolence and dizziness; withdrawal seizures upon abrupt discontinuation.
Hypersensitivity to dyphylline or any xanthine derivative. Uncontrolled arrhythmias. Active seizure disorder. Severe hypotension. Concurrent use with other xanthines (e.g., theophylline).
Absolute: Hypersensitivity to ELIXOMIN or any component; history of drug-induced liver injury; concomitant use with MAOIs. Relative: Hepatic impairment; renal insufficiency (Cr Cl <30 m L/min); pregnancy (teratogenic effects in animal studies).
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may increase adverse effects like nervousness and palpitations. No significant food interactions other than caffeine. Alcohol may increase CNS stimulation.
Grapefruit and grapefruit juice significantly increase ELIXOMIN plasma concentrations, increasing risk of toxicity. High-potassium foods (e.g., bananas, oranges, spinach) should be limited due to risk of hyperkalemia.
Lufyllin (dyphylline) is a xanthine derivative bronchodilator. Animal studies have not demonstrated teratogenicity. Human data are limited; however, as a methylxanthine, risks are considered low. First trimester: No evidence of major malformations. Second and third trimesters: No known fetal harm, but high doses may cause transient neonatal tachycardia or irritability due to placental transfer. Avoid use near term if possible due to potential neonatal effects.
ELIXOMIN is contraindicated in pregnancy (Category X). First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies. Second and third trimesters: Increased risk of spontaneous abortion, preterm delivery, and fetal growth restriction due to uteroplacental insufficiency.
Dyphylline is excreted into breast milk in small amounts. The milk-to-plasma ratio is approximately 0.7. Estimated infant dose is about 1-2% of maternal weight-adjusted dose. No adverse effects reported in breastfed infants. However, monitor for signs of irritability or sleep disturbances.
Not recommended during breastfeeding. Excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infant (e.g., nephrotoxicity, ototoxicity).
Pregnancy may alter the pharmacokinetics of methylxanthines due to increased plasma volume and decreased protein binding. However, dyphylline is not extensively protein-bound, so changes may be minimal. No specific dose adjustment is recommended, but monitor clinical response and toxicity. Avoid doses exceeding standard recommendations.
Due to increased glomerular filtration rate (GFR) in pregnancy, higher doses of ELIXOMIN may be required to achieve therapeutic drug levels. However, given teratogenicity, use is contraindicated; alternative therapy should be considered.
Dyphylline (Lufyllin) is a xanthine bronchodilator that is not metabolized to theophylline, making it an alternative for patients who cannot tolerate theophylline. It is 2-3 times less potent than theophylline, requiring higher doses. Renal excretion is the primary elimination route; dose adjustment is needed in renal impairment. Monitor drug interactions with cimetidine, quinolones, and macrolides, though less severe than with theophylline. Use with caution in patients with peptic ulcer, hyperthyroidism, or seizure disorders. Therapeutic levels are not well-defined, but target 6-18 mcg/m L for theophylline equivalents.
Monitor serum potassium levels closely; ELIXOMIN can cause life-threatening hyperkalemia especially in patients with renal impairment. Avoid concurrent use with potassium-sparing diuretics.
Take this medication exactly as prescribed, do not double doses if missed.,Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may increase side effects.,Report any signs of toxicity such as nausea, vomiting, insomnia, anxiety, or palpitations.,Do not crush or chew extended-release tablets unless instructed.,Maintain adequate hydration to help prevent side effects.,Inform your doctor if you are pregnant, breastfeeding, or have liver, kidney, or heart disease.
Do not consume grapefruit or grapefruit juice while taking ELIXOMIN.,Take with food to reduce gastrointestinal upset.,Report any muscle cramps, palpitations, or irregular heartbeat immediately.,Avoid potassium supplements and salt substitutes containing potassium.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LUFYLLIN vs ELIXOMIN, answered by our medical review team.
LUFYLLIN is a Xanthine Bronchodilator that works by LUFYLLIN (dyphylline) is a xanthine bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway hyperresponsiveness. It also antagonizes adenosine receptors.. ELIXOMIN is a Xanthine Bronchodilator that works by ELIXOMIN binds to and inhibits the N-methyl-D-aspartate (NMDA) receptor, reducing excitatory neurotransmission. It also modulates gamma-aminobutyric acid (GABA) activity, enhancing inhibitory signaling.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LUFYLLIN and ELIXOMIN depend on the specific clinical indication. These are both Xanthine Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LUFYLLIN is: 200-400 mg orally 3-4 times daily, not to exceed 1600 mg/day. Also available as 200 mg/m L injection, administer 200-400 mg IM or slow IV every 6-8 hours.. The standard adult dose of ELIXOMIN is: 500 mg orally once daily with a full glass of water, regardless of meals.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LUFYLLIN and ELIXOMIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LUFYLLIN is classified as Category C. Lufyllin (dyphylline) is a xanthine derivative bronchodilator. Animal studies have not demonstrated teratogenicity. Human data are limited; however, as a methylxanthine, risks are . ELIXOMIN is classified as Category C. ELIXOMIN is contraindicated in pregnancy (Category X). First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies. Second . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.